PT1244438E - Utilizacao de antagonistas dos receptores beta-adrenergicos para o fabrico de um medicamento destinado ao tratamento de perturbacoes da retina externa - Google Patents
Utilizacao de antagonistas dos receptores beta-adrenergicos para o fabrico de um medicamento destinado ao tratamento de perturbacoes da retina externaInfo
- Publication number
- PT1244438E PT1244438E PT00983818T PT00983818T PT1244438E PT 1244438 E PT1244438 E PT 1244438E PT 00983818 T PT00983818 T PT 00983818T PT 00983818 T PT00983818 T PT 00983818T PT 1244438 E PT1244438 E PT 1244438E
- Authority
- PT
- Portugal
- Prior art keywords
- antagonists
- perturbaces
- beta
- manufacture
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16799399P | 1999-11-30 | 1999-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1244438E true PT1244438E (pt) | 2004-02-27 |
Family
ID=22609644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT00983818T PT1244438E (pt) | 1999-11-30 | 2000-11-29 | Utilizacao de antagonistas dos receptores beta-adrenergicos para o fabrico de um medicamento destinado ao tratamento de perturbacoes da retina externa |
Country Status (18)
Country | Link |
---|---|
US (4) | US7081482B2 (pt) |
EP (1) | EP1244438B1 (pt) |
JP (2) | JP4758581B2 (pt) |
CN (1) | CN1245966C (pt) |
AT (1) | ATE253905T1 (pt) |
AU (1) | AU782524B2 (pt) |
BR (1) | BR0015938A (pt) |
CA (1) | CA2388728C (pt) |
DE (1) | DE60006584T2 (pt) |
DK (1) | DK1244438T3 (pt) |
ES (1) | ES2210023T3 (pt) |
HK (1) | HK1047695B (pt) |
MX (1) | MXPA02005378A (pt) |
PL (1) | PL214875B1 (pt) |
PT (1) | PT1244438E (pt) |
TR (1) | TR200302008T4 (pt) |
WO (1) | WO2001043737A1 (pt) |
ZA (1) | ZA200203133B (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2210023T3 (es) * | 1999-11-30 | 2004-07-01 | Alcon, Inc. | Uso de antagonistas de adrenoceptores neta para la fabricacion de un medicamento para el tratamiento de trastornos de la retina. |
CN100413503C (zh) * | 2005-01-07 | 2008-08-27 | 冷文 | 一种复方眼药组合物 |
US20080153819A1 (en) * | 2006-12-21 | 2008-06-26 | Bingaman David P | Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor |
KR20100133980A (ko) * | 2008-03-07 | 2010-12-22 | 썬 파마 어드밴스트 리서치 컴패니 리미티드 | 안약 조성물 |
US10267796B2 (en) * | 2010-10-25 | 2019-04-23 | The Procter & Gamble Company | Screening methods of modulating adrenergic receptor gene expressions implicated in melanogenesis |
CN110769855A (zh) * | 2017-04-21 | 2020-02-07 | 史蒂文·霍夫曼 | 用于治疗视网膜病变的组合物和方法 |
US11400070B2 (en) * | 2018-05-03 | 2022-08-02 | Alimera Sciences, Inc. | Methods of treating retinal diseases |
TWI776584B (zh) * | 2020-07-10 | 2022-09-01 | 長庚醫療財團法人林口長庚紀念醫院 | β-1腎上腺素受體拮抗劑用於製備減少表皮生長因子受體抑制劑誘導的上皮細胞損傷以及抑制癌細胞的組合物之用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2330383A1 (fr) | 1975-11-06 | 1977-06-03 | Synthelabo | Nouveaux ethers de phenols substitues, leurs sels, leur preparation et les medicaments qui les renferment |
US4443432A (en) | 1981-10-05 | 1984-04-17 | Alcon Laboratories, Inc. | Ophthmalic irrigating solution |
US5554367A (en) * | 1984-10-31 | 1996-09-10 | Alcon Laboratories, Inc. | Compositions for treatment of glaucoma |
US6066675A (en) | 1996-09-13 | 2000-05-23 | The Regents Of The University Of California | Method for treatment of retinal diseases |
WO2000018316A2 (en) * | 1998-09-25 | 2000-04-06 | Alcon Laboratories, Inc. | Sustained release, and comfortable ophthalmic composition and method for ocular therapy |
ES2210023T3 (es) | 1999-11-30 | 2004-07-01 | Alcon, Inc. | Uso de antagonistas de adrenoceptores neta para la fabricacion de un medicamento para el tratamiento de trastornos de la retina. |
-
2000
- 2000-11-29 ES ES00983818T patent/ES2210023T3/es not_active Expired - Lifetime
- 2000-11-29 PT PT00983818T patent/PT1244438E/pt unknown
- 2000-11-29 TR TR2003/02008T patent/TR200302008T4/xx unknown
- 2000-11-29 AT AT00983818T patent/ATE253905T1/de active
- 2000-11-29 US US10/130,408 patent/US7081482B2/en not_active Expired - Fee Related
- 2000-11-29 DE DE60006584T patent/DE60006584T2/de not_active Expired - Lifetime
- 2000-11-29 EP EP00983818A patent/EP1244438B1/en not_active Expired - Lifetime
- 2000-11-29 CA CA002388728A patent/CA2388728C/en not_active Expired - Fee Related
- 2000-11-29 JP JP2001544676A patent/JP4758581B2/ja not_active Expired - Fee Related
- 2000-11-29 PL PL356001A patent/PL214875B1/pl unknown
- 2000-11-29 WO PCT/US2000/032575 patent/WO2001043737A1/en active IP Right Grant
- 2000-11-29 AU AU20527/01A patent/AU782524B2/en not_active Ceased
- 2000-11-29 DK DK00983818T patent/DK1244438T3/da active
- 2000-11-29 MX MXPA02005378A patent/MXPA02005378A/es active IP Right Grant
- 2000-11-29 CN CNB008163510A patent/CN1245966C/zh not_active Expired - Fee Related
- 2000-11-29 BR BR0015938-7A patent/BR0015938A/pt not_active Application Discontinuation
-
2002
- 2002-04-19 ZA ZA200203133A patent/ZA200203133B/en unknown
- 2002-11-16 HK HK02108325.7A patent/HK1047695B/zh not_active IP Right Cessation
-
2006
- 2006-05-02 US US11/415,824 patent/US20060199868A1/en not_active Abandoned
-
2008
- 2008-01-04 US US11/969,346 patent/US20080103211A1/en not_active Abandoned
-
2010
- 2010-06-09 US US12/796,942 patent/US8710102B2/en not_active Expired - Fee Related
- 2010-07-06 JP JP2010154379A patent/JP2010215667A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20080103211A1 (en) | 2008-05-01 |
DE60006584D1 (de) | 2003-12-18 |
WO2001043737A1 (en) | 2001-06-21 |
US8710102B2 (en) | 2014-04-29 |
JP2003516963A (ja) | 2003-05-20 |
US7081482B2 (en) | 2006-07-25 |
DK1244438T3 (da) | 2004-02-23 |
MXPA02005378A (es) | 2005-02-25 |
CN1245966C (zh) | 2006-03-22 |
AU2052701A (en) | 2001-06-25 |
EP1244438B1 (en) | 2003-11-12 |
HK1047695A1 (en) | 2003-03-07 |
CN1402634A (zh) | 2003-03-12 |
AU782524B2 (en) | 2005-08-04 |
ZA200203133B (en) | 2003-04-22 |
EP1244438A1 (en) | 2002-10-02 |
CA2388728A1 (en) | 2001-06-21 |
US20100249134A1 (en) | 2010-09-30 |
ATE253905T1 (de) | 2003-11-15 |
JP2010215667A (ja) | 2010-09-30 |
BR0015938A (pt) | 2002-08-27 |
JP4758581B2 (ja) | 2011-08-31 |
ES2210023T3 (es) | 2004-07-01 |
DE60006584T2 (de) | 2004-09-30 |
PL214875B1 (pl) | 2013-09-30 |
TR200302008T4 (tr) | 2004-01-21 |
US20020193373A1 (en) | 2002-12-19 |
HK1047695B (zh) | 2004-08-20 |
PL356001A1 (en) | 2004-05-31 |
CA2388728C (en) | 2009-05-19 |
US20060199868A1 (en) | 2006-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL144643A0 (en) | Jak-3 inhibitors for treating allergic disorders | |
EE200200274A (et) | Pürrolidiinatseetamiidi derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud kesknärvisüsteemi häirete ravimiseks, ja farmatseutiline kompositsioon | |
BR0312933A (pt) | Composição farmacêutica, unidade de dosagem farmacêutica, método para tratar uma ou mais doenças associadas com uma condição vascular, e, combinação terapêutica | |
PT1263504E (pt) | Compostos com actividade 5-ht1a uteis para o tratamento de perturbacoes da retina externa | |
PL352229A1 (en) | Prosthesis of sclera for treatment of presbyopia and other sight disorders | |
HK1074577A1 (en) | The use of thymosin ß4 (Tß4), analogues, isoforms and other derivatives in the manufacture of a medicament for treating disorders of eye and the surrounding tissue | |
BR9908510A (pt) | Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana | |
SE9704644D0 (sv) | New use | |
BR0210013A (pt) | Gel oftálmico de pirenzepina | |
PT946157E (pt) | Utilizacao topica de agonistas kapa-opioides para o tratamento da dor ocular | |
PT1244438E (pt) | Utilizacao de antagonistas dos receptores beta-adrenergicos para o fabrico de um medicamento destinado ao tratamento de perturbacoes da retina externa | |
AR023687A1 (es) | Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa | |
TR200200014T2 (tr) | Nörotik düzensizliklerin tedavisi. | |
EE200100553A (et) | Saredutandi ja selle farmatseutiliselt vastuvõetavate soolade kasutamine meeleoluhäirete, kohanemishäirete või segatüüpi ärev-depressiivsete häirete raviks või vältimiseks kasulike ravimite valmistamiseks | |
PT966285E (pt) | Utilizacao de (+)mefloquina para o tratamento da malaria | |
RS52011B (sr) | Nova primena derivata taksoida | |
EE200100689A (et) | IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon | |
DK0871446T3 (da) | Anvendelse af eliprodil til fremstilling af et lægemiddel til behandling af ischaemiske sygdomme i nethinden eller den optiske nerve | |
BG105984A (bg) | Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението | |
AR026062A1 (es) | Tratamiento de desordenes oculares | |
EE200200670A (et) | S-metüüldihüdroziprasidoon psühhiaatriliste ja silmahaiguste raviks | |
EP1632235A3 (en) | Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders | |
BG108033A (en) | Use of 2-amino-1-(4-hydroxy-2-methane sulphonamidophenyl)ethanol for treating urinary incontinence. | |
AUPQ330599A0 (en) | Novel agents for treatment and diagnosis of ocular disorders |